Disc Medicine, Inc. filed an 8-K with the U.S. Securities and Exchange Commission on September 10, 2026, disclosing initial results from the Phase 2 RESTORE-PV clinical trial of DISC-3405 in patients with polycythemia vera.
Key Highlights
- Trial enrollment: The RESTORE-PV trial enrolled 40 adult participants with polycythemia vera, with 20 in Cohort A and 20 in Cohort B.
- Phlebotomy reduction: Among the 13 Cohort A participants completing 26 weeks, mean total phlebotomy events decreased from 4.0 to 0.6 in 26 weeks post-Day 1 (p<0.0001), according to the filing.
- Phlebotomy-free rate: 61.5% of the 13 participants who completed 26 weeks remained entirely phlebotomy-free post-baseline through 26 weeks.
- Maintenance period: Of those completing the first maintenance period (weeks 12-32, n=9), 77.8% remained phlebotomy-free during that period.
- Hematocrit control: Mean hematocrit was maintained stably below 45% through week 26 in Cohort A, which the company reported led to initial improvement in symptom burden.
- Tolerability: The filing states DISC-3405 "was generally well-tolerated with adverse events that are consistent with underlying disease and a low rate of injection site reactions which were mild and self-limited" in Cohorts A and B.
RESTORE-PV Phase 2 Data: Dosing, Efficacy, and Safety Findings for DISC-3405
Disc Medicine, Inc. (NASDAQ:IRON) disclosed initial results from its Phase 2, multi-center, open-label RESTORE-PV trial through an Item 8.01 filing on September 9, 2026. The trial is evaluating DISC-3405, administered subcutaneously, in adult patients with polycythemia vera. According to the filing, participants undergo a 4- to 12-week observation period, followed by a 12-week dose escalation phase, before receiving DISC-3405 at 300 mg every two weeks (Cohort A) or every four weeks (Cohort B) for 20 weeks, with up to 20 additional weeks of treatment at the respective doses.
At the time of the data cut, the company reported all 20 Cohort A participants had been dosed, with 13 completing 26 weeks of study, while 18 of 20 Cohort B participants had been dosed. Efficacy data were announced for Cohort A, while baseline and safety data were reported for both cohorts. The filing noted dose-proportional pharmacokinetics, elevation of hepcidin, reduction of serum iron, and an increase in ferritin in Cohort A across escalation and maintenance periods.
The primary efficacy signal in Cohort A centered on phlebotomy reduction. The filing states mean total phlebotomy events decreased significantly from 4.0 in the 26 weeks at baseline to 0.6 in the 26 weeks following Day 1 among participants who completed 26 weeks of study (n=13), with a p-value of less than 0.0001. The press release containing these results was attached as Exhibit 99.1 and furnished under Item 7.01. The company noted that the information furnished under Item 7.01 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
What Was Disclosed
Disc Medicine disclosed initial Phase 2 RESTORE-PV trial results for DISC-3405 in polycythemia vera patients, covering efficacy data for Cohort A and baseline and safety data for both cohorts, as of September 9, 2026.




Please wait processing your request...